EGFR inhibitors in the treatment of colorectal cancer
This ar cle discusses the use of EGFR inhibitors in the treatment of pa ents with colorectal cancer. The mechanisms of their ac on, specifi c manifesta ons of toxicity are considered. A review of current literature data on the use of both approved for clinical use (cetuximab, panitumumab) and an -EGF...
Main Authors: | M. В. Zabelin, A. D. Kaprin, A. A. Kostin, E. V. Gameeva, S. E. Varlamova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
QUASAR, LLC
2018-09-01
|
Series: | Issledovaniâ i Praktika v Medicine |
Subjects: | |
Online Access: | https://www.rpmj.ru/rpmj/article/view/295 |
Similar Items
-
Role of antiangiogenic agents in the treatment of metastatic colorectal cancer
by: M. V. Zabelin, et al.
Published: (2018-05-01) -
New therapeutic agents for metastatic colorectal cancer: literature review
by: M. V. Zabelin, et al.
Published: (2018-12-01) -
c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors
by: Antonia Strippoli, et al.
Published: (2020-03-01) -
THE NECESSITY OF ADVANCED RAS-MUTATIONS INVESTIGATION FOR COLORECTAL CANCER TREATMENT
by: V. A. Gorbunova
Published: (2015-02-01) -
LINE-1 Expression is Associated with the Effectiveness of EGFR Inhibitors in Colorectal Cancer Cells
by: Eiichiro Yamamoto, et al.
Published: (2020-09-01)